Compound News and Research

RSS

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

27 Oct 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

Super broccoli on the shelves to protect from heart disease

British scientists unveiled a new breed of broccoli that experts say packs heavy on nutritional values. The new broccoli was specially grown to contain two to three times the normal amount of glucoraphanin, a nutrient believed to help ward off heart disease. Glucoraphanin breaks fat down in the body, preventing it from clogging the arteries.

27 Oct 2011

BPA exposure in mothers may affect unborn daughters’ behavior: Study

A new federal study revealed Monday in the journal Pediatrics shows that bisphenol A (BPA) - a chemical used widely in plastic bottles, metal cans and other consumer products could be linked to behavioral and emotional problems in toddler girls.

25 Oct 2011

Research questions aromatherapy safety

Aromatherapy oils are relied upon to relax, reduce stress and soothe aches and pains by many. However researchers from Chia-Nan University of Pharmacy and Science Tainan, Taiwan say these oils may not be completely harmless.

24 Oct 2011

Taconic and Oncodesign announce agreement to co-promote and co-develop solutions to advance oncology research

Taconic, a leading provider of life sciences solutions, and Oncodesign(R), an innovative leader in the discovery of novel anti-cancer therapies, announce today that they have entered into an agreement to co-develop and co-promote pre-clinical oncology in vivo solutions for researchers worldwide. The agreement provides researchers with improved access to a large, diverse portfolio of translational models for use in pre-clinical oncology studies, along with supporting scientific services.

24 Oct 2011

Encap Drug Delivery and Lena Nanoceutics to develop new drug delivery technology

Encap Drug Delivery and Lena Nanoceutics today announce a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) which combines Lena’s proprietary nano-particle engineering technology with Encap’s liquid filled hard capsule technology.

24 Oct 2011

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Today Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis.

22 Oct 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

Effective, safe care depends on coordination across primary and secondary healthcare service levels

The Norwegian healthcare services are organized in primary and secondary service levels. According to PhD student Kristin Laugaland at UiS effective and safe care depends on coordination across the two service levels in which transitions across them represent a crucial stage in the recovery of elderly people.

21 Oct 2011

New metabolic pathway for controlling brain inflammation

A team led by scientists from The Scripps Research Institute has identified a new metabolic pathway for controlling brain inflammation, suggesting strategies for treating it.

21 Oct 2011

JHU, Eisai enter drug-discovery research collaboration for brain disorders

The Johns Hopkins University (JHU) has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer's disease.

20 Oct 2011

Scientists determine structure of GAG proteoglycan

If genes provide the blueprint for life and proteins are the machines that do much of the work for cells, then carbohydrates that are linked to proteins are among the tools that enable cells to communicate with the outside world and each other. But until now, scientists have been unable to determine the structure of a biologically important so-called GAG proteoglycan-or even to agree whether these remarkably complex molecules have well-defined structures.

19 Oct 2011

Oral laquinimod shows promise against multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability progression and brain volume loss.

19 Oct 2011

Brain scans can evaluate new treatments for attention deficit disorder

Scientists have developed a way to evaluate new treatments for some forms of attention deficit disorder. Working in mice, researchers at Washington University School of Medicine in St. Louis showed that they can use brain scans to quickly test whether drugs increase levels of a brain chemical known as dopamine.

15 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

IRMS tracks course of designer 'legal high' drugs manufacture

Urgently needed tests which could help identify the manufacturers of designer 'legal high' drugs are being developed in research led at the University of Strathclyde in Glasgow.

14 Oct 2011

Scientists conclude pesticide contamination as a major problem in Europe

Pesticides are a bigger problem than had long been assumed. This is the conclusion of a study in which scientists analysed data on 500 organic substances in the basins of four major European rivers. It was revealed that 38 per cent of these chemicals are present in concentrations which could potentially have an effect on organisms.

14 Oct 2011

Study: Green vegetables boost immune function

Researchers reporting online in the journal Cell, a Cell Press publication, on October 13th have found another good reason to eat your green vegetables, although it may or may not win any arguments with kids at the dinner table.

14 Oct 2011

Study reveals new regulatory elements in human genome

An international research team led by Kerstin Lindblad-Toh at the Broad Institute, US and Uppsala University, Sweden has mapped and compared the genomes of 29 mammals. The findings, published in Nature, reveal millions of new regulatory elements in the human genome that in various ways govern how proteins are formed. The new knowledge is important for our understanding of how mutations in human genes give rise to diseases.

13 Oct 2011